SMA Clinical Trials

2,025 recruitingLast updated: July 25, 2026

There are 2,025 actively recruiting sma clinical trials across 95 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


SMA Trials at a Glance

2,025 actively recruiting trials for sma are listed on ClinicalTrialsFinder across 6 cities in 95 countries. The largest study group is Phase 2 with 774 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running sma studies include AstraZeneca, National Cancer Institute (NCI), and Memorial Sloan Kettering Cancer Center.

Treatments under study

About SMA Clinical Trials

Looking for clinical trials for SMA? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new SMA trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about SMA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 2,025 trials

Recruiting
Phase 1

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Boehringer Ingelheim300 enrolled12 locationsNCT04429087
Recruiting
Phase 3

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI)300 enrolled604 locationsNCT04181060
Recruiting

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Non-small Cell Lung Cancer
Regeneron Pharmaceuticals500 enrolled49 locationsNCT05363319
Recruiting
Not Applicable

Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases

Brain Metastases From Breast CancerBrain Metastases From Non-small Cell Lung Cancer (NSCLC)Brain Metastases From Melanoma
The Netherlands Cancer Institute100 enrolled1 locationNCT07511933
Recruiting
Phase 3

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Extensive-stage Small-cell Lung Cancer
BioNTech SE621 enrolled221 locationsNCT06712355
Recruiting
Phase 2Phase 3

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Extensive Stage Lung Small Cell Carcinoma
National Cancer Institute (NCI)138 enrolled416 locationsNCT04402788
Recruiting
Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Hepatocellular CarcinomaLocally Advanced MelanomaMetastatic Hepatocellular Carcinoma+7 more
National Cancer Institute (NCI)30 enrolled1 locationNCT06066138
Recruiting
Phase 3

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Lung Non-Small Cell Carcinoma
National Cancer Institute (NCI)336 enrolled18 locationsNCT07388524
Recruiting

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Non-small Cell Lung CancerSmall Cell Lung CancerExtrapulmonary Small Cell Cancer+2 more
National Cancer Institute (NCI)2,000 enrolled1 locationNCT02146170
Recruiting
Phase 1

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer
Nerviano Medical Sciences10 enrolled3 locationsNCT06931626
Recruiting
Phase 3

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled199 locationsNCT07195695
Recruiting
Phase 2

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Neuroendocrine CarcinomaCarcinoma, NeuroendocrineTumor, Neuroendocrine+2 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06406465
Recruiting
Phase 2

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Metastatic Non-small Cell Lung Cancer (NSCLC)Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb160 enrolled71 locationsNCT07680764
Recruiting
Not Applicable

Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

Paroxysmal AF
Medtronic Cardiac Ablation Solutions300 enrolled24 locationsNCT07308847
Recruiting
Phase 3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1151 locationsNCT04267848
Recruiting
Phase 1

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

Recurrent Plasmablastic LymphomaRefractory Plasmablastic Lymphoma
National Cancer Institute (NCI)30 enrolled1 locationNCT07332507
Recruiting
Phase 3

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)304 enrolled322 locationsNCT06096844
Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 3

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

CLLLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic+3 more
Merck Sharp & Dohme LLC735 enrolled55 locationsNCT05947851
Recruiting

Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery

SarcopeniaLung Cancer (Non-Small Cell)Malnutrition Severe
Ondokuz Mayıs University142 enrolled1 locationNCT07500376